# US 2026/0226556 A1 · Method for detecting genomic rearrangements

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0226556 A1
- Document ID: US20260226556A1
- Status: Published application
- Kind: A1
- Application number: 19/287,662
- Filed: 2025-07-31
- Published: 2026-08-06
- Earliest claimed: 2017-06-16
- Assignees: Inivata Ltd.
- Applicants: Inivata Ltd.
- Inventors: Samuel Woodhouse; Stefanie Lensing; Tim Forshew; Vincent Plagnol; Matthew Edward Smith; Karen Howarth; Michael Epstein
- Web page: https://patentgrep.com/patent/US20260226556A1

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12Q 1/6806: Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay (C12Q1/6804 takes precedence)
- C12Q 1/6853: using modified primers or templates
- C12Q 1/686: Polymerase chain reaction [PCR]
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q 2600/16: Primer sets for multiplex assays
- G16B 20/00: ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B 30/00: ICT specially adapted for sequence analysis involving nucleotides or amino acids
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY

## Abstract

The present disclosure relates to methods for detecting and targeting genomic rearrangements, in particular gene fusion events, by targeting a DNA molecule of interest with a set or pool of primers, wherein the forward primers and reverse primers produce a PCR amplification product when a genomic rearrangement is present. The present disclosure also relates to methods of bioinformatic analysis to determine whether or not the detection of an amplification product from the selective PCR is actually indicative of the presence of a gene fusion. The present disclosure also related to related methods of diagnosis and treatment of diseases and conditions associated with such genomic rearrangements, in particular cancers, such as lung cancer.

## Claims

### Claim at position 1

1-117. (canceled)

### Claim 118

A method for determining whether a subject has minimal residual disease, comprising:
(a) performing a polymerase chain reaction (PCR) on a nucleic acid sample from the subject using a forward primer and a reverse primer to produce amplification products;
(b) sequencing the amplification products produced in step (a), or amplification product made from the same, to produce sequence reads;
(c) identifying sequence reads that correspond to a genetic alteration by:
(i) identifying sequence reads which have the sequence of the forward primer used in step (a), or complement thereof, at one end and the sequence of the reverse primer used in step (a), or a complement thereof, at the other end;
(ii) for each sequence read identified in (c)(i), determining whether the sequence read comprises a sequence that matches a sequence in a first region of the reference human genome and is downstream of the sequence of the forward primer; and
(iii) for each sequence read identified in (c)(i), determining whether the sequence read comprises a sequence that matches a sequence in a second region of the reference human genome and is downstream of the sequence of the reverse primer;
wherein an amplification product that corresponds to the genetic alteration comprises the sequence of the forward primer used in step (a) at one end, the sequence of the reverse primer used in step (a) at the other end, a sequence that matches a sequence in the first region of the reference human genome, and a sequence that matches a sequence in the second region of the reference human genome; and
(d) determining that the subject has minimal residual disease based on the genetic alteration identified in step (c).

### Claim 119 (depends on 118)

The method of claim 118, wherein:
step (c)(ii) comprises, for each sequence read identified in (c)(i), determining whether the sequence read comprises a sequence that matches a sequence that is immediately adjacent to the sequence of the forward primer of the sequence read in the first region of the reference human genome; and step (c)(iii) comprises, for each sequence read identified in (c)(i), determining whether the sequence read comprises a sequence that matches a sequence that is immediately adjacent to the sequence of the reverse primer of the sequence read in the second region of the reference human genome.

### Claim 120 (depends on 119)

The method of claim 119, wherein:
step (c)(ii) comprises determining whether the sequence in the sequence read has sufficient base pairs that uniquely match or does not have sufficient base pairs that uniquely match to the sequence that is downstream from the sequence of the forward primer in the reference genome; and
step (c)(iii) comprises determining whether the sequence in the sequence read has sufficient base pairs that uniquely match or does not have sufficient base pairs that uniquely match to the sequence that is downstream from the sequence of the reverse primer of the sequence read in the reference genome.

### Claim 121 (depends on 120)

The method of claim 120, wherein:
i. the sequence read has sufficient base pairs that uniquely match when the sequence immediately downstream from the sequence of the primer in the sequence read matches only the sequence immediately downstream from the sequence of the primer in the reference genome; and
ii. the sequence read does not have sufficient base pairs that uniquely match when the sequence immediately downstream from the sequence of the primer in the sequence read matches the sequence immediately downstream from the sequence of the primer in the reference genome as well as other sequences in the reference genome.

### Claim 122 (depends on 120)

The method of claim 120, wherein a sequence read that corresponds to a genetic alteration comprises the sequence of a forward primer used in step (a) at one end, the sequence of a reverse primer used in step (a) at the other end, a sequence that has sufficient base pairs that uniquely match to a sequence in the first region of the reference human genome, and a sequence that has sufficient base pairs that uniquely match to a sequence in the second region of the reference human genome.

### Claim 123 (depends on 120)

The method of claim 120, wherein a sequence read that corresponds to a genetic alteration comprises the sequence of a forward primer used in step (a) at one end, the sequence of a reverse primer used in step (a) at the other end, a sequence that has sufficient base pairs that uniquely match to a sequence in the first region of the reference human genome, and a sequence that has sufficient base pairs that uniquely match to a sequence in the second region of the reference human genome, only if the same sequence is observed in a replicate genetic alteration-specific PCR reaction.

### Claim 124 (depends on 118)

The method of claim 118, wherein the identifying sequence reads of (c) corresponds to a plurality of genetic alterations.

### Claim 125 (depends on 124)

The method of claim 124, wherein a genetic alteration of the plurality of genetic alternations comprises a structural variant, wherein a structural variant comprises a gene fusion, a duplication, an insertion, a deletion, a copy number variation, an inversion or a translocation.

### Claim 126 (depends on 124)

The method of claim 124, wherein a genetic alteration of the plurality of genetic alternations comprises an indel, a gene fusion, a copy number variation, or combination thereof.

### Claim 127 (depends on 118)

The method of claim 118, wherein the nucleic acid sample comprises cell free DNA.

### Claim 128 (depends on 118)

The method of claim 118, wherein the genetic alternation comprises a structural variant, wherein a structural variant comprises a gene fusion, a duplication, an insertion, a deletion, a copy number variation, an inversion or a translocation.

### Claim 129 (depends on 118)

The method of claim 118, wherein the genetic alteration comprises an indel, a gene fusion, or a copy number variation.

### Claim 130 (depends on 118)

The method of claim 118, wherein the genetic alteration comprises a single nucleotide mutation.
